Consistent with the rapid onset of transgene expression mediated by adenovirus vectors (refs. 58, 59 and Supplemental Figure 9), by 36 hours after injection we found a reduction (P < 0.05) in the number of convulsive seizures in CAV-SCN1A–injected Scn1aA1783V/WT mice, compared with DS mice injected with CAV-GFP (Figure 6B and Supplemental Figure 8). This evidence concerns the gene SCN1A and Dravet syndrome.